1. Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis
- Author
-
Seren, Seda, Rashed Abouzaid, Maha, Eulenberg-Gustavus, Claudia, Hirschfeld, Josefine, Nasr Soliman, Hala, Jerke, Uwe, N'Guessan, Koffi, Dallet-Choisy, Sandrine, Lesner, Adam, Lauritzen, Conni, Schacher, Beate, Eickholz, Peter, Nagy, Nikoletta, Szell, Marta, Croix, Cécile, Viaud-Massuard, Marie-Claude, Al Farraj Aldosari, Abdullah, Ragunatha, Shivanna, Ibrahim Mostafa, Mostafa, Giampieri, Francesca, Battino, Maurizio, Cornillier, Hélène, Lorette, Gérard, Stephan, Jean-Louis, Goizet, Cyril, Pedersen, John, Gauthier, Francis, Jenne, Dieter E., Marchand-Adam, Sylvain, Chapple, Iain L., Kettritz, Ralph, Korkmaz, Brice, Pathologies Respiratoires : Protéolyse et Aérosolthérapie, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), National Research Center, Helmholtz-Gemeinschaft = Helmholtz Association, University of Birmingham, Medical & Molecular Genetics, University of Birmingham, School of Clinical and Experimental Medicine, Faculty of Chemistry, Technion - Israel Institute of Technology [Haifa], Unizyme Laboratories A/S, Partenaires INRAE, Department of Periodontology, People's Liberation Army No. 309 Hospital, Department of Medical Genetics, University Hospital of North-Norway, Centre National de la Recherche Scientifique (CNRS), King Saud University [Riyadh] (KSU), Department of Dermatology, Venereology, and Leprosy, Sri Siddhartha Medical College, Department of Clinical Sciences, Swedish University of Agricultural Sciences (SLU), Service de dermatologie, Infectiologie et Santé Publique (UMR ISP), Institut National de la Recherche Agronomique (INRA)-Université de Tours (UT), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) (U1211 INSERM/MRGM), Université de Bordeaux (UB)-Groupe hospitalier Pellegrin-Institut National de la Santé et de la Recherche Médicale (INSERM), German Centre for Lung Research, Max Planck Institute of Neurobiology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Ministère de l'Enseignement Supérieur et de la Recherche, the 'Région Centre-Val de Loire' (Project BPCO-Lyse), European Project: 668036,H2020,H2020-PHC-2015-two-stage,RELENT(2015), ProdInra, Migration, RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities - RELENT - - H20202015-11-01 - 2020-04-30 - 668036 - VALID, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Institut National de la Recherche Agronomique (INRA)-Université de Tours, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Subjects
Adult ,Male ,neutrophile ,Adolescent ,Neutrophils ,cathepsin C ,Myeloblastin ,Papillon-Lefèvre syndrome ,Médecine humaine et pathologie ,cathepsine ,autoimmune disease ,Cysteine Proteinase Inhibitors ,activation cellulaire ,protease inhibitor ,Young Adult ,antigen ,genetic disease ,cellule souche ,Humans ,cardiovascular diseases ,Child ,hématopoïèse ,aminopeptidase ,granulomatosis with polyangiitis ,neutrophil ,protease ,proteinase 3 ,maladie autoimmune ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Cell Membrane ,inhibiteur pharmacologique ,Case-Control Studies ,Child, Preschool ,Proteolysis ,Enzymology ,Female ,Human health and pathology ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Membrane-bound proteinase 3 (PR3m) is the main target antigen of anti-neutrophil cytoplasmic autoantibodies (ANCA) in granulomatosis with polyangiitis, a systemic small-vessel vasculitis. Binding of ANCA to PR3m triggers neutrophil activation with the secretion of enzymatically active PR3 and related neutrophil serine proteases, thereby contributing to vascular damage. PR3 and related proteases are activated from pro-forms by the lysosomal cysteine protease cathepsin C (CatC) during neutrophil maturation. We hypothesized that pharmacological inhibition of CatC provides an effective measure to reduce PR3m and therefore has implications as a novel therapeutic approach in granulomatosis with polyangiitis. We first studied neutrophilic PR3 from 24 patients with Papillon-Lefèvre syndrome (PLS), a genetic form of CatC deficiency. PLS neutrophil lysates showed a largely reduced but still detectable (0.5-4%) PR3 activity when compared with healthy control cells. Despite extremely low levels of cellular PR3, the amount of constitutive PR3m expressed on the surface of quiescent neutrophils and the typical bimodal membrane distribution pattern were similar to what was observed in healthy neutrophils. However, following cell activation, there was no significant increase in the total amount of PR3m on PLS neutrophils, whereas the total amount of PR3m on healthy neutrophils was significantly increased. We then explored the effect of pharmacological CatC inhibition on PR3 stability in normal neutrophils using a potent cell-permeable CatC inhibitor and a CD34+ hematopoietic stem cell model. Human CD34+ hematopoietic stem cells were treated with the inhibitor during neutrophil differentiation over 10 days. We observed strong reductions in PR3m, cellular PR3 protein, and proteolytic PR3 activity, whereas neutrophil differentiation was not compromised.
- Published
- 2018